Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Total Debt (2019)

Quantum Biopharma's Total Debt history spans 1 years, with the latest figure at $2.0 million for Q4 2019.

  • On a quarterly basis, Total Debt changed N/A to $2.0 million in Q4 2019 year-over-year; TTM through Dec 2019 was $2.0 million, a N/A change, with the full-year FY2019 number at $2.0 million, changed N/A from a year prior.
  • Total Debt hit $2.0 million in Q4 2019 for Quantum Biopharma.
  • Over the last five years, Total Debt for QNTM hit a ceiling of $2.0 million in Q4 2019 and a floor of $2.0 million in Q4 2019.